Skip to content

Subscription price for Promore Pharma’s warrants TO1 determined

STOCKHOLM, January 31, 2019 – The subscription price for warrant TO1 in Promore Pharma AB (publ) has been determined according to the terms and conditions for the warrants to 23.30 SEK per share.

The subscription period starts 4 February and continues until 22 February 2019.

For additional information, please contact

Jonas Ekblom, President and CEO

Phone: [+46] 736 777 540


Jenni Björnulfson, CFO

Phone: [+46] 708 55 38 05


Promore Pharma’s Certified Adviser is Redeye. 

Phone: [+46] 8 121 576 90 


Promore Pharma in brief

Promore Pharma is a biopharmaceutical company specialized in the development of therapeutic peptides. The company’s aim is to develop first-in-category pharmaceuticals for indications where very few efficacious prescription pharmaceuticals are available, thus, addressing high unmet medical needs. Promore Pharma’s two projects are in late stage clinical development phase and have a very strong safety profile since they are based on innate substances that are administered locally. The leading project, PXL01, that will be used for prevention of post-surgical adhesions and scars, is being prepared for clinical phase III-studies in patients undergoing tendon repair surgery in the hand. LL-37 has initiated a clinical phase IIb study in patients with venous leg ulcers (VLU). The product candidates can also be deployed for other indications, such as preventing dermal scarring, adhesions after other surgical procedures and treatment of diabetic foot ulcers. The company is listed on Nasdaq First North.